Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients
Objective. To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus- (HCV-) positive advanced hepatocellular carcinoma (HCC). Patients and Methods. Patients diagnosed with HCV-positive advanced HCC were eligible for this study. A maximum of four HLA-mat...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2015/473909 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554742410117120 |
|---|---|
| author | Shigeru Yutani Kazuomi Ueshima Kazumichi Abe Atsushi Ishiguro Junichi Eguchi Satoko Matsueda Nobukazu Komatsu Shigeki Shichijo Akira Yamada Kyogo Itoh Tetsuro Sasada Masatoshi Kudo Masanori Noguchi |
| author_facet | Shigeru Yutani Kazuomi Ueshima Kazumichi Abe Atsushi Ishiguro Junichi Eguchi Satoko Matsueda Nobukazu Komatsu Shigeki Shichijo Akira Yamada Kyogo Itoh Tetsuro Sasada Masatoshi Kudo Masanori Noguchi |
| author_sort | Shigeru Yutani |
| collection | DOAJ |
| description | Objective. To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus- (HCV-) positive advanced hepatocellular carcinoma (HCC). Patients and Methods. Patients diagnosed with HCV-positive advanced HCC were eligible for this study. A maximum of four HLA-matched peptides were selected based on the preexisting IgG responses specific to 32 different peptides, which consisted of a single HCV-derived peptide at core protein positions 35–44 (C-35) and 31 peptides derived from 15 different tumor-associated antigens (TAAs), followed by subcutaneous administration once per week for 8 weeks. Peptide-specific cytotoxic T lymphocyte (CTL) and IgG responses were measured before and after vaccination. Results. Forty-two patients were enrolled. Grade 3 injection site skin reaction was observed in 2 patients, but no other PPV-related severe adverse events were noted. Peptide-specific CTL responses before vaccination were observed in only 3 of 42 patients, but they became detectable in 23 of 36 patients tested after vaccination. Peptide-specific IgG responses were also boosted in 19 of 36 patients. Peptide-specific IgG1 responses to both C-35 and TAA-derived peptides could be potentially prognostic for overall survival. Conclusion. Further clinical study of PPV would be warranted for HCV-positive advanced HCC, based on the safety and strong immune induction. |
| format | Article |
| id | doaj-art-f65dc6484858478386d04aac92977eb3 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-f65dc6484858478386d04aac92977eb32025-02-03T05:50:50ZengWileyJournal of Immunology Research2314-88612314-71562015-01-01201510.1155/2015/473909473909Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma PatientsShigeru Yutani0Kazuomi Ueshima1Kazumichi Abe2Atsushi Ishiguro3Junichi Eguchi4Satoko Matsueda5Nobukazu Komatsu6Shigeki Shichijo7Akira Yamada8Kyogo Itoh9Tetsuro Sasada10Masatoshi Kudo11Masanori Noguchi12Cancer Vaccine Center, Kurume University, Kurume 839-0863, JapanDepartment of Gastroenterology and Hepatology, Kinki University Faculty of Medicine, Osaka 589-8511, JapanDepartment of Digestive, Rheumatism and Collagen Internal Medicine, Fukushima Prefectural Medical College, Fukushima 960-1295, JapanDepartment of Medical Oncology, Hirosaki University Graduate School of Medicine, Hirosaki 036-8562, JapanDepartment of Gastroenterology, Showa University School of Medicine, Tokyo 142-8555, JapanCancer Vaccine Center, Kurume University, Kurume 839-0863, JapanDepartment of Immunology, Kurume University School of Medicine, Kurume 830-0011, JapanCancer Vaccine Center, Kurume University, Kurume 839-0863, JapanResearch Center for Innovative Cancer Therapy, Kurume University, Kurume 830-0011, JapanCancer Vaccine Center, Kurume University, Kurume 839-0863, JapanCancer Vaccine Center, Kurume University, Kurume 839-0863, JapanDepartment of Gastroenterology and Hepatology, Kinki University Faculty of Medicine, Osaka 589-8511, JapanResearch Center for Innovative Cancer Therapy, Kurume University, Kurume 830-0011, JapanObjective. To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus- (HCV-) positive advanced hepatocellular carcinoma (HCC). Patients and Methods. Patients diagnosed with HCV-positive advanced HCC were eligible for this study. A maximum of four HLA-matched peptides were selected based on the preexisting IgG responses specific to 32 different peptides, which consisted of a single HCV-derived peptide at core protein positions 35–44 (C-35) and 31 peptides derived from 15 different tumor-associated antigens (TAAs), followed by subcutaneous administration once per week for 8 weeks. Peptide-specific cytotoxic T lymphocyte (CTL) and IgG responses were measured before and after vaccination. Results. Forty-two patients were enrolled. Grade 3 injection site skin reaction was observed in 2 patients, but no other PPV-related severe adverse events were noted. Peptide-specific CTL responses before vaccination were observed in only 3 of 42 patients, but they became detectable in 23 of 36 patients tested after vaccination. Peptide-specific IgG responses were also boosted in 19 of 36 patients. Peptide-specific IgG1 responses to both C-35 and TAA-derived peptides could be potentially prognostic for overall survival. Conclusion. Further clinical study of PPV would be warranted for HCV-positive advanced HCC, based on the safety and strong immune induction.http://dx.doi.org/10.1155/2015/473909 |
| spellingShingle | Shigeru Yutani Kazuomi Ueshima Kazumichi Abe Atsushi Ishiguro Junichi Eguchi Satoko Matsueda Nobukazu Komatsu Shigeki Shichijo Akira Yamada Kyogo Itoh Tetsuro Sasada Masatoshi Kudo Masanori Noguchi Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients Journal of Immunology Research |
| title | Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients |
| title_full | Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients |
| title_fullStr | Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients |
| title_full_unstemmed | Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients |
| title_short | Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients |
| title_sort | phase ii study of personalized peptide vaccination with both a hepatitis c virus derived peptide and peptides from tumor associated antigens for the treatment of hcv positive advanced hepatocellular carcinoma patients |
| url | http://dx.doi.org/10.1155/2015/473909 |
| work_keys_str_mv | AT shigeruyutani phaseiistudyofpersonalizedpeptidevaccinationwithbothahepatitiscvirusderivedpeptideandpeptidesfromtumorassociatedantigensforthetreatmentofhcvpositiveadvancedhepatocellularcarcinomapatients AT kazuomiueshima phaseiistudyofpersonalizedpeptidevaccinationwithbothahepatitiscvirusderivedpeptideandpeptidesfromtumorassociatedantigensforthetreatmentofhcvpositiveadvancedhepatocellularcarcinomapatients AT kazumichiabe phaseiistudyofpersonalizedpeptidevaccinationwithbothahepatitiscvirusderivedpeptideandpeptidesfromtumorassociatedantigensforthetreatmentofhcvpositiveadvancedhepatocellularcarcinomapatients AT atsushiishiguro phaseiistudyofpersonalizedpeptidevaccinationwithbothahepatitiscvirusderivedpeptideandpeptidesfromtumorassociatedantigensforthetreatmentofhcvpositiveadvancedhepatocellularcarcinomapatients AT junichieguchi phaseiistudyofpersonalizedpeptidevaccinationwithbothahepatitiscvirusderivedpeptideandpeptidesfromtumorassociatedantigensforthetreatmentofhcvpositiveadvancedhepatocellularcarcinomapatients AT satokomatsueda phaseiistudyofpersonalizedpeptidevaccinationwithbothahepatitiscvirusderivedpeptideandpeptidesfromtumorassociatedantigensforthetreatmentofhcvpositiveadvancedhepatocellularcarcinomapatients AT nobukazukomatsu phaseiistudyofpersonalizedpeptidevaccinationwithbothahepatitiscvirusderivedpeptideandpeptidesfromtumorassociatedantigensforthetreatmentofhcvpositiveadvancedhepatocellularcarcinomapatients AT shigekishichijo phaseiistudyofpersonalizedpeptidevaccinationwithbothahepatitiscvirusderivedpeptideandpeptidesfromtumorassociatedantigensforthetreatmentofhcvpositiveadvancedhepatocellularcarcinomapatients AT akirayamada phaseiistudyofpersonalizedpeptidevaccinationwithbothahepatitiscvirusderivedpeptideandpeptidesfromtumorassociatedantigensforthetreatmentofhcvpositiveadvancedhepatocellularcarcinomapatients AT kyogoitoh phaseiistudyofpersonalizedpeptidevaccinationwithbothahepatitiscvirusderivedpeptideandpeptidesfromtumorassociatedantigensforthetreatmentofhcvpositiveadvancedhepatocellularcarcinomapatients AT tetsurosasada phaseiistudyofpersonalizedpeptidevaccinationwithbothahepatitiscvirusderivedpeptideandpeptidesfromtumorassociatedantigensforthetreatmentofhcvpositiveadvancedhepatocellularcarcinomapatients AT masatoshikudo phaseiistudyofpersonalizedpeptidevaccinationwithbothahepatitiscvirusderivedpeptideandpeptidesfromtumorassociatedantigensforthetreatmentofhcvpositiveadvancedhepatocellularcarcinomapatients AT masanorinoguchi phaseiistudyofpersonalizedpeptidevaccinationwithbothahepatitiscvirusderivedpeptideandpeptidesfromtumorassociatedantigensforthetreatmentofhcvpositiveadvancedhepatocellularcarcinomapatients |